Oncology & Cancer

CAR T therapy shows long-lasting remissions in non-hodgkin lymphoma

A significant number of non-Hodgkin lymphoma (NHL) patients in a Penn Medicine-initiated clinical trial continue to be in remission five years after receiving the chimeric antigen receptor (CAR) T cell therapy Kymriah, researchers ...

Oncology & Cancer

Novel index IDs prognosis in adults with Burkitt lymphoma

(HealthDay)—The Burkitt lymphoma (BL) International Prognostic Index (BL-IPI) provides robust discrimination of survival and can be used for prognostication, according to a study published online Jan. 27 in the Journal ...

Oncology & Cancer

A new, potent weapon against lymphomas

MDC researchers have developed a new approach to CAR T-cell therapy. The team has shown in Nature Communications that the procedure is very effective, especially when it comes to fighting follicular lymphomas and chronic ...

page 4 from 12